Aerie Pharmaceuticals Announces U.S. FDA Approval of Rhopressa® (netarsudil ophthalmic solution) 0.02% for the Lowering of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension

Read also

Recordati Considers €10.9B CVC Capital Acquisition Offer Before Q1 Close

Italian pharma Recordati weighs a €10.9bn acquisition offer from CVC Capital. Discover the details of this major M&A deal ahead of the Q1 2026 close.

Simulations Plus and Pharma Partners Advance AI-Driven Drug Development

Simulations Plus announces strategic partnerships with three pharmaceutical companies to integrate AI into model-informed drug development workflows.

Wave Life Sciences Stock Plummets 50% on Weak Phase I Obesity Trial Data

Wave Life Sciences' stock crashed 50% after its Phase I obesity trial for WVE-007 showed lower-than-expected weight loss, disappointing investors.

FDA Approves Novo Nordisk's Awiqli®: First Once-Weekly Insulin for T2D

The FDA has approved Novo Nordisk's Awiqli®, the first and only once-weekly basal insulin treatment for adults living with type 2 diabetes to improve A1C.